Clinical Trials
28 trialsNCT05879146 2026-05-15
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04093596 2026-05-13
UNIVERSAL
Allogene Therapeutics
Phase 1 Completed
NCT04722146 2026-05-08
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05041036 2026-05-08
Individual Patient Compassionate Use of Nirogacestat
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Available
NCT07170644 2026-05-08
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2 Active not recruiting
NCT07176689 2026-05-08
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 4 Recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07084896 2026-05-06
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT05090566 2026-04-24
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Terminated
NCT04195399 2026-04-15
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Children's Oncology Group
Phase 2 Active not recruiting
NCT05556798 2026-02-24
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05137054 2026-01-22
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT05348356 2025-12-15
Nirogacestat in Ovarian Granulosa Cell Tumors
SpringWorks Therapeutics, Inc.
Phase 2 Completed
NCT05949099 2025-09-08
Study of Cryoablation and Nirogacestat for Desmoid Tumor
Stanford University
Phase 2 Recruiting
NCT07150091 2025-09-02
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07150104 2025-09-02
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT03785964 2025-01-31
DeFi
SpringWorks Therapeutics, Inc.
Phase 3 Completed
NCT01981551 2024-02-06
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05573802 2023-10-24
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
Phase 1/2 Recruiting
NCT04171843 2023-09-21
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Precision BioSciences, Inc.
Phase 1 Terminated
NCT00878189 2019-11-12
A Trial In Patients With Advanced Cancer And Leukemia
Pfizer
Phase 1 Completed
NCT01876251 2019-03-15
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Pfizer
Phase 1 Terminated
NCT02955446 2019-02-01
Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
University of Colorado, Denver
No longer available
NCT02109445 2019-01-10
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
Pfizer
Phase 2 Terminated
NCT02299635 2019-01-08
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Pfizer
Phase 2 Terminated
NCT02338531 2016-04-29
RHEA
Jules Bordet Institute
Phase 2 Withdrawn
NCT02462707 2015-10-07
A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors
Pfizer
Phase 1 Withdrawn
NCT02137564 2015-07-23
Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
AIDS Malignancy Consortium
Phase 2 Withdrawn